Man Group PLC Allakos Inc. Transaction History

Man Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $83,080 - $121,159	-23,078 Reduced 68.0%	10,861 $47,000
Q1 2023 May 15, 2023	SELL	$4.3 - $8.27 $89,663 - $172,446	-20,852 Reduced 38.06%	33,939 $151,000
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $1,313 - $1,953	232 Added 0.43%	54,791 $461,000
Q3 2022 Nov 14, 2022	SELL	$3.02 - $6.12 $29,007 - $58,782	-9,605 Reduced 14.97%	54,559 $334,000
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $16,286 - $38,460	6,264 Added 10.82%	64,164 $201,000
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $294,132 - $567,999	57,900 New	57,900 $330,000
Q3 2020 Nov 16, 2020	SELL	$66.43 - $90.99 $4.53 Million - $6.2 Million	-68,155 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $2.75 Million - $5.03 Million	62,396 Added 1083.45%	68,155 $4.9 Million
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $143,880 - $302,023	3,234 Added 128.08%	5,759 $256,000
Q4 2019 Feb 18, 2020	SELL	$66.49 - $137.73 $999,876 - $2.07 Million	-15,038 Reduced 85.62%	2,525 $241,000
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $544,453 - $1.58 Million	17,563 New	17,563 $1.38 Million

68.8M

20.9K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $24.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.